Suppr超能文献

急性血清生物标志物对创伤性脑损伤后功能结局的增量预后价值(CENTER-TBI):一项观察性队列研究

Incremental prognostic value of acute serum biomarkers for functional outcome after traumatic brain injury (CENTER-TBI): an observational cohort study.

作者信息

Helmrich Isabel R A Retel, Czeiter Endre, Amrein Krisztina, Büki András, Lingsma Hester F, Menon David K, Mondello Stefania, Steyerberg Ewout W, von Steinbüchel Nicole, Wang Kevin K W, Wilson Lindsay, Xu Haiyan, Yang Zhihui, van Klaveren David, Maas Andrew I R

机构信息

Center for Medical Decision Making, Department of Public Health, Erasmus University Medical Center, Rotterdam, Netherlands.

Department of Neurosurgery, Medical School, and Neurotrauma Research Group, Szentágothai Research Centre, University of Pécs, Pécs, Hungary; MTA-PTE Clinical Neuroscience MR Research Group, Pécs, Hungary.

出版信息

Lancet Neurol. 2022 Sep;21(9):792-802. doi: 10.1016/S1474-4422(22)00218-6.

Abstract

BACKGROUND

Several studies have reported an association between serum biomarker values and functional outcome following traumatic brain injury. We aimed to examine the incremental (added) prognostic value of serum biomarkers over demographic, clinical, and radiological characteristics and over established prognostic models, such as IMPACT and CRASH, for prediction of functional outcome.

METHODS

We used data from the Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI) core study. We included patients aged 14 years or older who had blood sampling within 24 h of injury, results from a CT scan, and outcome assessment according to the Glasgow Outcome Scale-Extended (GOSE) at 6 months. Amounts in serum of six biomarkers (S100 calcium-binding protein B, neuron-specific enolase, glial fibrillary acidic protein, ubiquitin C-terminal hydrolase L1 [UCH-L1], neurofilament protein-light, and total tau) were measured. The incremental prognostic value of these biomarkers was determined separately and in combination. The primary outcome was the GOSE 6 months after injury. Incremental prognostic value, using proportional odds and a dichotomised analysis, was assessed by delta C-statistic and delta R between models with and without serum biomarkers, corrected for optimism with a bootstrapping procedure.

FINDINGS

Serum biomarker values and 6-month GOSE were available for 2283 of 4509 patients. Higher biomarker levels were associated with worse outcome. Adding biomarkers improved the C-statistic by 0·014 (95% CI 0·009-0·020) and R by 4·9% (3·6-6·5) for predicting GOSE compared with demographic, clinical, and radiological characteristics. UCH-L1 had the greatest incremental prognostic value. Adding biomarkers to established prognostic models resulted in a relative increase in R of 48-65% for IMPACT and 30-34% for CRASH prognostic models.

INTERPRETATION

Serum biomarkers have incremental prognostic value for functional outcome after traumatic brain injury. Our findings support integration of biomarkers-particularly UCH-L1-in established prognostic models.

FUNDING

European Union's Seventh Framework Programme, Hannelore Kohl Stiftung, OneMind, Integra LifeSciences, and NeuroTrauma Sciences.

摘要

背景

多项研究报告了血清生物标志物值与创伤性脑损伤后功能结局之间的关联。我们旨在研究血清生物标志物相对于人口统计学、临床和放射学特征以及相对于既定的预后模型(如IMPACT和CRASH)在预测功能结局方面的增量(附加)预后价值。

方法

我们使用了欧洲创伤性脑损伤协作神经创伤有效性研究(CENTER-TBI)核心研究的数据。我们纳入了14岁及以上在受伤后24小时内进行血液采样、有CT扫描结果以及在6个月时根据扩展格拉斯哥结局量表(GOSE)进行结局评估的患者。测量了六种生物标志物(S100钙结合蛋白B、神经元特异性烯醇化酶、胶质纤维酸性蛋白、泛素C末端水解酶L1 [UCH-L1]、神经丝轻链蛋白和总tau蛋白)的血清含量。分别并联合确定这些生物标志物的增量预后价值。主要结局是受伤后6个月的GOSE。使用比例优势和二分法分析,通过有和没有血清生物标志物的模型之间的delta C统计量和delta R评估增量预后价值,并通过自举程序校正乐观性。

结果

4509例患者中有2283例获得了血清生物标志物值和6个月的GOSE。生物标志物水平越高,结局越差。与人口统计学、临床和放射学特征相比,添加生物标志物在预测GOSE方面使C统计量提高了0.014(95%CI 0.009-0.020),R提高了4.9%(3.6-6.5)。UCH-L1具有最大的增量预后价值。将生物标志物添加到既定的预后模型中,IMPACT预后模型的R相对增加了48-65%,CRASH预后模型的R相对增加了30-34%。

解读

血清生物标志物对创伤性脑损伤后的功能结局具有增量预后价值。我们的研究结果支持将生物标志物——尤其是UCH-L1——纳入既定的预后模型中。

资金来源

欧盟第七框架计划、汉内洛尔·科尔基金会、OneMind、Integra LifeSciences和NeuroTrauma Sciences。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验